First- and Second-Generation Antipsychotics for Children and Young Adults
Clinical Questions Addressed by the Comparative Effectiveness Review (2 of 2)
Key Questions addressed by the review included:
Do first-generation (FGAs) and second-generation (SGAs) antipsychotics differ in the following medication-associated adverse events:
- Overall adverse events?
- Specific adverse events?
- Withdrawals and time to withdrawal due to adverse events?
- Persistence and reversibility of adverse events?
Do the efficacy and risks of FGAs and SGAs vary in differing subpopulations including:
- Sex, age group, and race?
- Cotreatment versus monotherapy?
- First episode versus prior episodes (for schizophrenia)?
- Duration of illness?
- Treatment naïve versus history of antipsychotic use?
- Seida J, Schouten J, Mousavi S, et al. First- and Second-Generation Antipsychotics for Children and Young Adults. Comparative Effectiveness Review No. 39 (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021). Rockville, MD: Agency for Healthcare Research and Quality; February 2012. AHRQ Publication No. 11(12)-EHC077-EF. Available at www.effectivehealthcare.ahrq.gov/pedantipsych.cfm.
Your slide tray is being processed.